Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study

被引：0

作者：

Ballard, Morgan ^{[1
]}

Toukatly, Mirna ^{[2
]}

Bean, Gregory ^{[3
]}

Jalikis, Florencia ^{[4
]}

Krings, Gregor ^{[3
]}

Schmidt, Rodney ^{[4
]}

Chen, Yunn-Yi ^{[3
]}

Dintzis, Suzanne

Troxell, Megan ^{[5
]}

West, Robert ^{[6
]}

Sibley, Richard ^{[5
]}

Allison, Kimberly ^{[6
]}

机构：

[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[3] UCSF, San Francisco, CA USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[6] Stanford Univ, Stanford, CA 94305 USA

来源：

MODERN PATHOLOGY | 2018年 / 31卷

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

139

引用

页码：47 / 48

页数：2

共 50 条

[11] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
MODERN PATHOLOGY, 2018, 31 : 45 - 45
[12] Breast Cancer With a HER2 IHC2+and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
Liu, Yuanyuan
Wu, Shafei
Shi, Xiaohua
Mao, Feng
Zeng, Xuan
FRONTIERS IN ONCOLOGY, 2020, 10
[13] HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features
Zare, Somaye
Lin, Leo
Alghamdi, Abrar G.
Roma, Andres
Dell'Aquila, Marie
Hasteh, Farnaz
Fadare, Oluwole
MODERN PATHOLOGY, 2018, 31 : 117 - 117
[14] Utility of HER2 Immunohistochemistry in Clarifying HER2 Status in Breast Cancer with HER2:CEP17 Ratio <2 and Average >/=4.0 and <6.0 HER2 Signals per Tumor Cell by Fluorescence in-situ Hybridization (Focused Update Group 4)
Muller, Kristen
Marotti, Jonathan
Tafe, Laura
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 223 - 223
[15] Utility of HER2 Immunohistochemistry in Clarifying HER2 Status in Breast Cancer with HER2:CEP17 Ratio <2 and Average >/=4.0 and <6.0 HER2 Signals per Tumor Cell by Fluorescence in-situ Hybridization (Focused Update Group 4)
Muller, Kristen
Marotti, Jonathan
Tafe, Laura
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 223 - 223
[16] HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features
Zare, Somaye
Lin, Leo
Alghamdi, Abrar G.
Roma, Andres
Dell'Aquila, Marie
Hasteh, Farnaz
Fadare, Oluwole
LABORATORY INVESTIGATION, 2018, 98 : 117 - 117
[17] A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell
Wang, Xiaoling
Teng, Xiaodong
Ding, Wei
Sun, Ke
Wang, Bo
MODERN PATHOLOGY, 2020, 33 (08) : 1557 - 1562
[18] Incidence and Significance of Fluorescent In Situ Hybridization (FISH) HER2 Gene Amplification by HER2 Gene Copy Number of ≥6.0 with Her2/CEP17 Ratio of <2.0 in Breast Cancer
Apple, Sophia
MODERN PATHOLOGY, 2017, 30 : 29A - 30A
[19] Incidence and Significance of Fluorescent In Situ Hybridization (FISH) HER2 Gene Amplification by HER2 Gene Copy Number of ≥ 6.0 with Her2/CEP17 Ratio of <2.0 in Breast Cancer
Apple, Sophia
LABORATORY INVESTIGATION, 2017, 97 : 29A - 30A
[20] Association between HER2 positivity by HER2/CEP17 ratio and response to neoadjuvant HER2 targeted therapy.
Rappazzo, Katherine Cynthia
Chen, Heidi
Ballinger, Tarah Jean
Abramson, Vandana Gupta
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →

Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio &gt; 2.0 but &lt; 4 HER2 signals/cell; A Multi-Institutional Study

Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study